BRYAN, Texas--(BUSINESS WIRE)--Nutrabolt, a globally recognized leader in sports nutrition whose brand portfolio includes the award winning Cellucor® and Scivation® brands of dietary supplements, is proud to announce that it has partnered with Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, to extend its license to patented CarnoSyn® beta-alanine through 2026.
On June 6, 2017, the U.S. Patent and Trademark Office issued a new patent to NAI directed to a broad range of improved methods of beta-alanine intake, targeting such benefits as delaying muscle fatigue, increasing anaerobic capacity, increasing muscle strength and increasing muscle endurance. This new intellectual property significantly extends the patent coverage for CarnoSyn® beta-alanine. Nutrabolt, given its market dominance in sports nutrition and vision for the future of nutrition in sports and other fields, was a natural business partner for NAI. Nutrabolt is proud to include the patented, trademarked, and clinically studied CarnoSyn® beta-alanine in several of its products, including its award winning C4® brand of pre-workout products. CarnoSyn® beta-alanine is not only included in the category leading C4® Original pre-workout product but is included in a variety of newly released C4® branded products including C4 Ripped®, C4 Sport®, C4 Extreme EnergyTM, C4 Ultimate® and its ready to drink formula C4 On The Go®.
As the only clinically studied form of beta-alanine, CarnoSyn® beta-alanine has been shown to provide numerous performance enhancing benefits including an increase in muscular endurance, making it the perfect addition to a pre-workout product engineered to improve performance. Nutrabolt is proud to display the CarnoSyn® logo on its C4® and other product labels and to continue to conduct University based clinical studies on the performance enhancing benefits of its formulas containing CarnoSyn® beta-alanine. Nutrabolt is proud to partner with NAI, who has a long history of investing significant monies funding research and brand awareness related to beta-alanine around the world, as well as vigorously protecting its intellectual property rights against infringers, providing further value to its licensees.
Doss Cunningham, CEO of Nutrabolt said that "since its inception in 2002, our company has focused on bringing new technology and innovative product solutions to the sports nutrition industry. We are also constantly looking at using high quality, patented ingredients, backed by strong science. NAI's CarnoSyn® beta-alanine is supported by dozens of scientific studies and a global intellectual property estate. We value and respect NAI's investment in research and IP surrounding CarnoSyn®. The notice of its recent patent allowance, extending its coverage of uses related to beta-alanine, led to very productive discussions with NAI about the future of beta-alanine, not just in sports nutrition, but other fields that are growing rapidly. Nutrabolt has always been a company that puts its customers first and constantly searches for innovative product offerings and improved methods of use. NAI's IP portfolio surrounding CarnoSyn® beta-alanine demonstrates, through science, methods of use that benefit consumers. We look forward to working with NAI in several areas and to promoting its patented CarnoSyn® beta-alanine as an ingredient in Nutrabolt products."
Mark A. LeDoux, NAI’s CEO and Chairman of the Board, said that “NAI is very excited by the execution of this agreement with Nutrabolt extending its worldwide license to our CarnoSyn® patent and trademark rights. The recent addition of NAI's new patent, directed to a broad range of improved methods of beta-alanine intake, is the future of beta-alanine in sports nutrition." LeDoux went on to say that "during our meetings with Nutrabolt executives and its research team, we explored other fields of use for CarnoSyn® that NAI holds patent rights to, uses beyond sports nutrition and for which it continues to explore through funded research around the world. The opportunity to work with a market leader like Nutrabolt related to CarnoSyn® was an easy decision for us."
Nutrabolt is a global nutritional life sciences company established in
2002 that specializes in consumer product solutions in sports nutrition
and functional foods. The Company’s marquee brand, Cellucor, includes
the brand’s most notable product line C4, which has become the
uncontested industry leader in pre-workout supplementation. Nutrabolt
also owns Royal Sport and through a recent acquisition, Scivation Inc.,
best known for its XTEND branded product line. Nutrabolt launched its
way into functional foods in 2016 through its FitJoy branded line of
healthy on-the-go protein based snacks. Nutrabolt’s brands are
distributed to some of the world’s largest specialty, big box and online
retailers including GNC, Vitamin Shoppe, Amazon.com, Bodybuilding.com,
Walmart, Costco, and Target. Nutrabolt’s brands are distributed in more
than 40 countries through its network of global distributors.
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI’s clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com or http://www.carnosyn.com.
This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.